Screener
Syndax Pharmaceuticals SNDX EPS (Basic)
EPS (Basic) at other companies
Other financials
Where this comes from
Reported directly by Syndax Pharmaceuticals in its filing.
Tagged under the XBRL concept us-gaap:EarningsPerShareBasic.
The source filing: Syndax Pharmaceuticals’s 10-Q, filed April 30, 2026.
- Filed
- Apr 30, 2026, 4:04 PM EDT
- Fiscal quarter
- Q1 FY2026
- Calendar quarter
- Q1 2026
- Accession
- 0001193125-26-197154
| Line item | Three Months Ended March 31, 2026 | Three Months Ended March 31, 2025 |
|---|---|---|
| Net loss | $(42,673) | $(84,846) |
| Other Comprehensive loss: | ||
| Unrealized (loss) gain on marketable securities | (441) | 364 |
| Other Comprehensive loss | (43,114) | (84,482) |
| Net loss per share: | ||
| Basic and diluted loss per share attributable to common stockholders | $(0.48) | $(0.98) |
| Weighted-average common shares used in calculating: | ||
| Basic and diluted loss per share attributable to common stockholders | 88,255,636 | 86,171,889 |
Item 1: Financial Statements
FAQ
- What is Syndax Pharmaceuticals's EPS (basic)?
- Syndax Pharmaceuticals (SNDX) reported EPS (basic) of -$0.48 in Q1 2026.
- How has Syndax Pharmaceuticals's EPS (basic) changed year-over-year?
- Syndax Pharmaceuticals's EPS (basic) increased by 51.0% year-over-year, from -$0.98 to -$0.48.
- What is the long-term trend for Syndax Pharmaceuticals's EPS (basic)?
- Over 3 years (2022 to 2025), Syndax Pharmaceuticals's EPS (basic) has grown at a 10.3% compound annual growth rate (CAGR), from -$2.45 to -$3.29.
- What does EPS (basic) mean?
- Net income available to common shareholders divided by the weighted-average number of common shares outstanding during the period. Does not account for dilutive securities.
Ask your AI about Syndax Pharmaceuticals's eps (basic).
Connect your AI assistant and compare it to peers, right in your chat.
Connect your AI
Claude